Compare SCLX & GROV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCLX | GROV |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.1M | 52.1M |
| IPO Year | 2020 | 2021 |
| Metric | SCLX | GROV |
|---|---|---|
| Price | $5.86 | $0.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $1.60 |
| AVG Volume (30 Days) | ★ 59.5K | 24.7K |
| Earning Date | 04-10-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | N/A | ★ N/A |
| Revenue | $30,253,000.00 | ★ $173,716,000.00 |
| Revenue This Year | $122.52 | N/A |
| Revenue Next Year | $186.30 | $6.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.20 | $1.01 |
| 52 Week High | $34.27 | $1.59 |
| Indicator | SCLX | GROV |
|---|---|---|
| Relative Strength Index (RSI) | 33.68 | 36.46 |
| Support Level | $5.48 | N/A |
| Resistance Level | $7.77 | $1.17 |
| Average True Range (ATR) | 0.42 | 0.06 |
| MACD | -0.08 | -0.00 |
| Stochastic Oscillator | 13.24 | 34.25 |
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Grove Collaborative Holdings Inc is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with a human and environmental focus. The Company sells its products through a direct-to-consumer (DTC) platform and the Company's mobile applications, where the Company sells products from Grove-owned brands (Grove Brands) and third-parties.